The Young Heart: What Camzyos' SCOUT-HCM Data Means for Adolescents with Obstructive HCM

There is a particular kind of clinical trial result that does more than expand a drug's label. It reframes what a disease means for an entirely different group of patients. Bristol Myers Squibb's Phase 3 SCOUT-HCM data, presented this weekend at the American College of Cardiology's Annual Scientific Session in New Orleans, is one of those results.

Camzyos (mavacamten), the cardiac myosin inhibitor that has already reshaped how cardiologists treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), has now demonstrated efficacy and safety in adolescents. The SCOUT-HCM trial met its primary endpoint, showing a clinically meaningful and statistically significant reduction in left ventricular outflow tract (LVOT) obstruction, the defining hemodynamic problem in oHCM, in patients aged 12 to 17. It is the first Phase 3 trial of any cardiac myosin inhibitor in a pediatric population.

Why Adolescents With oHCM Have Been Underserved

Hypertrophic cardiomyopathy is the most common inherited cardiac condition, affecting roughly 1 in 500 people. In its obstructive form, the thickened heart muscle creates a dynamic blockage of blood flow out of the left ventricle, producing symptoms that range from exertional breathlessness and chest pain to syncope and, in the most severe cases, sudden cardiac death. The disease does not wait for adulthood. Many patients are diagnosed in their teens, often after a murmur is detected during a sports physical or following a frightening episode during exercise.

Until Camzyos arrived for adults in 2022, the treatment toolkit for oHCM was largely unchanged for decades: beta-blockers, calcium channel blockers, and, for refractory cases, invasive procedures like surgical myectomy or alcohol septal ablation. These interventions carry real risks in any patient, but they carry particular weight in a 14-year-old who has decades of life ahead. The absence of a targeted, disease-modifying oral therapy for adolescents was not a minor gap. It was a structural failure of the field.

What the SCOUT-HCM Data Actually Show

The SCOUT-HCM trial enrolled adolescents with symptomatic oHCM and randomized them to mavacamten or placebo in a double-blind, controlled design. The drug achieved its primary endpoint, reducing LVOT gradient, and hit several secondary endpoints related to symptoms and functional capacity. The safety profile was consistent with what has been observed in adults, with the key monitored risk being a reduction in left ventricular ejection fraction, which remained manageable and reversible in the trial population.

The data were presented as a late-breaking oral presentation on Sunday, March 29, at ACC.26, the same meeting where BMS also shared multiple real-world evidence analyses from adult oHCM registries including DISCOVER-HCM, MARVEL-HCM, and COMPASS-HCM. Taken together, the body of evidence presented this weekend represents the most comprehensive dataset ever assembled for a cardiac myosin inhibitor, spanning from newly diagnosed adults to adolescents, from clinical trials to real-world practice.

The Broader Significance for Cardiovascular Drug Development

The SCOUT-HCM result matters beyond the immediate patient population for several reasons. First, it validates the mechanism. Mavacamten works by selectively inhibiting cardiac myosin ATPase, reducing the hypercontractility that drives LVOT obstruction. The fact that this mechanism translates cleanly into adolescents, whose hearts are still developing, suggests the biology of oHCM is consistent across age groups in ways that were not previously confirmed in a controlled trial.

Second, it sets a precedent for how the cardiovascular field approaches pediatric drug development. Historically, children and adolescents with cardiac conditions have been treated with adult drugs at adjusted doses, with limited trial data to support those decisions. SCOUT-HCM is a reminder that purpose-built pediatric trials are achievable and necessary, and that the regulatory pathway for pediatric indications, while demanding, can be navigated successfully.

Third, the commercial implications are real but secondary to the clinical ones. Camzyos is already approved in more than 60 countries for adults. A pediatric indication would extend the drug's reach to a population that currently has no approved targeted therapy, and it would do so at a point in the disease course where early intervention may prevent the structural remodeling that makes oHCM progressively harder to manage over time. Treating a 15-year-old before irreversible fibrosis sets in is a fundamentally different proposition than treating a 55-year-old who has lived with the disease for decades.

What Comes Next

BMS will need to submit the SCOUT-HCM data to the FDA and other regulatory agencies to seek a pediatric label expansion. Given the strength of the primary endpoint and the consistency of the safety profile with the adult experience, the regulatory path appears straightforward, though not guaranteed. The FDA's pediatric review process involves additional scrutiny, and the agency will want to see that the REMS program governing Camzyos in adults, which requires regular echocardiographic monitoring of ejection fraction, can be implemented effectively in adolescent patients and their families.

For the broader oHCM community, the SCOUT-HCM data arrive at a moment when the field is genuinely optimistic. A second cardiac myosin inhibitor, aficamten from Cytokinetics, is also in late-stage development, and competition in this space is likely to intensify. But competition in a previously underserved disease area is not a problem. It is a sign that the science has matured enough to attract sustained investment, and that patients, including the youngest ones, are finally being seen.

The heart does not distinguish between a teenager and an adult when it begins to thicken. The science, at last, is catching up.